Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy

BACKGROUND: With the rising number of chimeric antigen receptor (CAR) T cell treated patients, it is increasingly important to understand the treatment’s impact on patient-reported outcomes (PROs) and, ideally, identify biomarkers of central nervous system (CNS) adverse effects. METHODS: The purpose...

Descripción completa

Detalles Bibliográficos
Autores principales: Knight, Jennifer M., Szabo, Aniko, Arapi, Igli, Wu, Ruizhe, Emmrich, Amanda, Hackett, Edward, Sauber, Garrett, Yim, Sharon, Johnson, Bryon, Hari, Parameswaran, Schneider, Dina, Dropulic, Boro, Cusatis, Rachel N., Cole, Steve W., Hillard, Cecilia J., Shah, Nirav N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098435/
https://www.ncbi.nlm.nih.gov/pubmed/35603278
http://dx.doi.org/10.1038/s43856-022-00116-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098435/
https://www.ncbi.nlm.nih.gov/pubmed/35603278
http://dx.doi.org/10.1038/s43856-022-00116-5

Ejemplares similares